Esomeprazole Magnesium Delayed-Release Capsules, USP 40 mg, packaged in Unit Dose Blister Cards o...

FDA Drug Recall #D-0861-2022 — Class II — April 1, 2022

Recall Summary

Recall Number D-0861-2022
Classification Class II — Moderate risk
Date Initiated April 1, 2022
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Location Rockford, IL
Product Type Drugs
Quantity 885 cartons

Product Description

Esomeprazole Magnesium Delayed-Release Capsules, USP 40 mg, packaged in Unit Dose Blister Cards of 6 (10 cards of 6 Capsules each per carton), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC 42292-010-16

Reason for Recall

Failed Impurities/Degradation Specifications: OOS result was obtained for Any Other Individual Impurity at the 12M room temperature time point.

Distribution Pattern

Nationwide within USA

Lot / Code Information

Lot #: 3110437, 3111409, 3110785, Exp. Date 7/31/2022; 3112173, Exp. Date 11/30/2022

Other Recalls from Mylan Institutional, Inc. (d.b.a. UDL...

Recall # Classification Product Date
D-0860-2022 Class II Esomeprazole Magnesium Delayed-Release Capsules... Apr 1, 2022
D-1013-2019 Class II Alprazolam Tablets, USP, 0.25 mg, 10x10 per car... Jan 18, 2019
D-1112-2018 Class III Diltiazem HCl Extended-release Capsules, USP 12... Aug 14, 2018
D-0823-2018 Class II Loxapine Capsules, USP 50 mg, packaged in 100 U... May 1, 2018
D-0822-2018 Class II Loxapine Capsules, USP 25 mg, packaged in 100 U... May 1, 2018

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.